Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL13280558 | 0.95 | HIF1A (0.48) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR | |
| Bromide SCHEMBL6428595 | 0.91 | HIF1A (0.44) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR | |
| Bromide SCHEMBL28548705 | 0.90 | HIF1A (0.40) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR | |
| SCHEMBL8379392 | 0.90 | HIF1A (0.43) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR | |
| Bromide SCHEMBL1582234 | 0.90 | HIF1A (0.43) | HIF1AALDH1A1TSHRSIGMAR1GAA | |
| SCHEMBL8373290 | 0.90 | HIF1A (0.43) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR | |
| Bromide SCHEMBL7559694 | 0.87 | HIF1A (0.38) | HIF1AALDH1A1SIGMAR1IDO1GAA | |
| Bromide SCHEMBL7559700 | 0.87 | HIF1A (0.38) | HIF1AALDH1A1SIGMAR1IDO1GAA | |
| Iodide SCHEMBL1969660 | 0.87 | HIF1A (0.44) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR | |
| Iodide SCHEMBL8182047 | 0.86 | HIF1A (0.40) | HIF1ACYP1A2CYP2D6ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025077841-A1 | AMIDE-SUBSTITUTED CYCLOALKYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USES THEREOF | 江苏恒瑞医药股份有限公司 | 2025-04-17 | — | — | WO | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| CN-113194721-B | Pesticidal compositions and methods | 科迪华农业科技有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004043916-A1 | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004018438-A2 | MICROBIOCIDAL (E.G. FUNGICIDAL) 1,2,3-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| EP-0970085-B1 | PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON ALPHA-AMINO ALKENES | CIBA SC HOLDING AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-6087070-A | AS PHOTOINITIATORS FOR BASE-CATALYZABLE REACTIONS | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0970085-A1 | PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON $g(a)-AMINO ALKENES | Ciba SC Holding AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998041524-A1 | PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON α-AMINO ALKENES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1998-09-24 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | HIF1A 4765/4885CYP1A2 3640/4885CYP2D6 297/4885 |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | HIF1A 3957/4885CYP1A2 3243/4885CYP2D6 1651/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | HIF1A 2856/4885CYP1A2 2573/4885CYP2D6 2836/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | HIF1A 4765/4885CYP1A2 3640/4885CYP2D6 297/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | HIF1A 4485/4885CYP1A2 4056/4885CYP2D6 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.